Novapep
Overview
Novapep, an Australian/US biotech, has developed a patented peptide structure called biparetideTM as an oral inflammatory bowel disease (IBD) therapy, which will be a cost effective, first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (the gold standard) and superior to corticosteroids, but with minimal expected side effects.
Novapep’s co-founders, Prof John Griffin and Prof Laurent Mosnier at the Scripps Research Institute in San Diego and Prof Chris Jackson at the University of Sydney have conducted over 15 years of ground breaking R&D in Activated Protein C (APC), which is anti-inflammatory, protects against unprogrammed cell death and has been shown to be effective in treating numerous diseases including inflammatory skin disorders and IBD. However, APC is very expensive to manufacture, needs to be stored at -70 C and is only being developed for high dose, intravenous administration in stroke and amyotrophic lateral sclerosis.
In response to APC's shortcomings, Novapep’s scientists invented a peptide structure called biparetide, which is a mimetic of APC, is more than an order of magnitude cheaper to manufacture and is stable at room temperature. The composition of matter patent for this invention was filed in 2019, which provides IP protection to 2039, with likely follow on patents, and it was licensed by Novapep from the Scripps in August, 2021. Novapep has previously raised ~$1,000,000 to optimise the molecule and conduct a number of animal studies demonatrating the efficacy of biparetide.
Novapep started a $1,000,000 equity capital raise in February and $350,000 has been raised to date. This funding will allow Novapep to progress its IBD program towards a Phase 1 clincial trial targetted to start at the end of 2025. Discussions are also underway with big pharma with the aim of concluding a partnering deal.
Problem and Solution
Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.
Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.
Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.
Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.
Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus mauris. Quisque volutpat pulvinar urna, posuere pharetra ex auctor vel. Sed id lacus tortor. Proin nisl turpis, tempus a leo in, lacinia volutpat orci.
Aenean nulla nibh, porta a dignissim vitae, laoreet vitae lacus. Nunc in aliquet urna. Vivamus vel turpis a mi consequat venenatis. Pellentesque tincidunt ante ut urna accumsan lacinia. Sed sed enim volutpat, malesuada metus ut, lobortis lectus. Sed vulputate fringilla justo, sed condimentum tellus fermentum sit amet. Pellentesque tempus elit id dapibus ornare. Phasellus accumsan suscipit elit. Donec eget libero eget neque cursus bibendum. Praesent lacinia felis et aliquam condimentum. Proin
Open an account to get
access to more details
Market Opportunity
Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.
Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rhoncus tempor fermentum. In malesuada tellus eu volutpat posuere. Nullam ut dignissim libero, ut pharetra leo. Nullam sit amet aliquam felis. Suspendisse volutpat ante eget tincidunt feugiat. Nunc placerat sapien et metus molestie, in viverra augue viverra. Donec varius metus ut arcu vestibulum hendrerit. Sed viv
Open an account to get
access to more details
Competitive Advantages
Cras eleifend purus vitae mattis imperdiet.
Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.
Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.
Fusce scelerisque massa sit amet turpis rutrum semper.
Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.
Proin non ipsum vel risus rutrum porta. Vivamus sem enim, interdum pretium metus eu, ornare posuere nisl. Duis vene
Open an account to get
access to more details
Highlights & Milestones
Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.
Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.
Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.
Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.
Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus mauris. Quisque volutpat pul
Open an account to get
access to more details
See more exiting opportunities on CapitalHQ
BetterX
BetterX offers B2B and B2B2C white-label and API driven software solutions to traditional institutions to offer digital asset services to their clients.
Paycepaid
Paycepaid is a Software as a Service debt collection solution unlike any on the market today with a heavy focus on the debtor. Empowering businesses to manage their end to end collections while providing debtors with a magnitude of options to reduce financial stress and anxiety.
Wholesale Investor
Wholesale Investor, with over 45,000 subscribers, is a leading private capital marketplace operating across Australia, Singapore, and the UK. It has a 15-year track record of connecting private market opportunities with HNW, professional, and family office investors. In just 4 years, our product...
PRIMAL ORGANIX
Primal Organix has created the world’s first botanically derived Terpene blended anti-anxiety health supplement that manages anxiety in minutes. Our purpose is to support positive mental ill-health and well-being in all human beings.
Sustainable Fintech Fund
Startupbootcamp, the #1 Accelerator in the world outside of the US, established in 2010, operates in 27 countries around the globe, has accelerated over 1600+ startups with a success rate of 76% remaining active, raised over $2.2B in total funding, a network of more than 300+ investors, 5000...
Misio
Sustainability performance and stakeholder communications are now fundamental to overall corporate profitability and impact. Misio simplifies a complex eco-system to help large & listed companies shift the sustainability narrative out from annual reports into easy to understand digital...
Pictor
Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...
National Property Group
National Property Group (NPG) is a trusted alternative provider of property data and insights empowering informed decisions for all property market participants. NPG relaunched its property data & analytics intelligence platform in 2021, delivering instant insights from more than 40 years of...
Novapep
Novapep, an Australian/US biotech, has developed a patented peptide structure called biparediteTM as an oral inflammatory bowel disease therapy, which will be a cost effective first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (a...
Backed By Leading Investment Groups and Family Offices
